Summary
HBV-infected immigrants from endemic countries.
3 A recent study suggests that 3.9% of the US population have been exposed to HBV, 0.3% have chronic HBV infection, and 25.1% have HBV vaccineinduced immunity. 4 It is estimated that over 70% of new US cases are imported chronic hepatitis B cases. 5 HBV infection is associated with a roughly 15% to 25% chance of death from cirrhosis or hepatocellular carcinoma (HCC) if left undiagnosed or without proper medical management. 6 However, most people with HBV infection remain unscreened, and the vaccination rate in high-risk persons is suboptimal.
7
Thus, it is an important public health issue to estimate the true burden of the disease and screen high-risk persons for both primary and secondary prevention.
The Centers for Diseases and Control Prevention (CDC) estimate that in 2013, non-Hispanic Asians, who are 5% of the nation's population, account for 50% of all chronic HBV infections in the United
States. 8 Additionally, the prevalence of HBV infection in non-Hispanic blacks is around twofold to threefold greater than the general population. 4 However, there are few epidemiological studies that have described the prevalence of HBV infection and immunity by racial group, especially including non-Hispanic Asians. From the [2011] [2012] cycle, the National Health Nutrition Examination Survey (NHANES), one of the most comprehensive national health surveys, began to include non-Hispanic Asian race information; they were oversampled to increase the number of Asian NHANES participants from <2% to upward of 13%. 4 Moreover, information about the awareness of HBV infection was included for the first time in the 2013-2014 cycle. 9 Thus, the aim of our study was to assess racial/ethnic disparities in the prevalence of HBV infection, previous exposure, and immunity to identify high-risk populations and estimate the awareness rate, using nationally representative data. did not substantially differ with respect to risk factors for HBV infection (age, sex and race). We excluded participants under 6 years of age as anti-HBc and HBsAg were not ascertained in that age group.
| METHODS

| Data Collection
The NHANES study was approved by the National Center for Health Statistics (NCHS) Research Ethics Review Board, and all participants provided written informed consent.
| Laboratory data
Collected blood specimens were processed, stored and shipped to the Division of Viral Hepatitis, National Center for Infectious Diseases (Atlanta, Georgia survey. Self-reported vaccination history was obtained from the immunization question, IMQ020: "Have you ever received the 3-dose series of the hepatitis B vaccine?"
| Study variables
| Statistical analysis
Data were analysed using R software version 3.2.2, using the "survey"
package. 16 We used appropriate analytic methodology and published weights for all analyses. 17 Appropriate weights were calculated for the 4-year period by halving the 2-year weights provided for NHANES 2011-2014. Data were age-adjusted using the direct standardization method according to NHANES analytic guidelines. 18 To describe the prevalence pattern of chronic HBV infection, past exposure and immunity within each racial-ethnic group, we estimated the prevalence by categories of study variables and calculated the adjusted odds ra- To our knowledge, this is the most comprehensive study to describe racial/ethnic disparities and awareness in HBV infection, past exposure and immunity, including Asians, using nationally representative data. Prior studies based on NHANES data were focused on F I G U R E 1 Prevalence of HBV chronic infection, past exposure and immunity 
| RESULTS
| Chronic HBV infection (HBsAg+)
OfT A B LE 2 Prevalence of Chronic Hepatitis B infection by racial/ethnic
32
The strengths of our study include that NHANES has begun to over-sample the Asian population, which provides a unique opportu- In conclusion, our findings suggest that the pattern of chronic HBV infection, past exposure and immunity varies significantly by racial/ethnic groups. Furthermore, awareness of the disease is still very low leading to a concern of late diagnosis with serious complications. The vaccine-induced immunity rate was still suboptimal despite the universal vaccination programme. More active and sophisticated healthcare policies regarding screening for HBV infection, vaccination, monitoring for immunity, targeted community outreach and education, and infection management may be warranted.
T A B L E 5 Awareness of HBV infection, liver disease and immunity
